Status: Not yet recruiting
Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients
The goal of this clinical trial is to evaluate the efficacy and safety of albumin-bound paclitaxel-lenvatinib-pembrolizumab in advanced nonsquamous NSCLC patients after progression to first-line anti-PD-1/L1 inhibitor with platinum-doublet chemotherapy. All participants will be given with albumin-bound paclitaxel, lenvatinib and pembrolizumab.
Participants needed: 28
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Peking University First HospitalUpdated: Sep 13, 2023Locations: 1
Eligibility criteria
Male/female participants who are at least 18 years of age on the day of signing... [+7]
A WOCBP who has a positive urine pregnancy test within 72 hours prior to treatme... [+29]